Home › Compare › EKIVF vs ABBV
EKIVF yields 3.65% · ABBV yields 3.06%● Live data
📍 EKIVF pulled ahead of the other in Year 2
Combined, EKIVF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EKIVF + ABBV for your $10,000?
Enka Insaat ve Sanayi A.S., together with its subsidiaries, operates as a construction company in Turkey, Russia, Kazakhstan, Georgia, Iraq, and internationally. It operates through four segments: Construction, Rental, Energy, and Trading and Manufacturing. The company engages in the construction of industrial and social buildings, and motorways; construction and operation of natural gas fired electrical energy generation facilities; and investment in and development of real estate properties and shopping malls. It is also involved in the marketing and after-sale service of construction machineries, trucks, industrial products, and spare parts; manufacturing of structural steel works; installation and establishment of the technical equipment; and excavation backfilling works and quarrying crushing operation of highway projects. In addition, the company engages in the pile dwelling work; base and superstructure construction; slip form and construction of drilling and ground surveys; organization of conventions and seminars; tour reservations and tickets sales; production of ready-mixed concrete; production and sale of electricity; repair and maintenance of power plants; and provision of architectural design and air transportation services, as well as trading activities. Further, it is involved in various activities, such as material handling and storage systems, auxiliary facilities, water treatment and environmental engineering, infrastructure and construction, control systems, and instrumentation engineering activities. Enka Insaat ve Sanayi A.S. was incorporated in 1957 and is headquartered in Istanbul, Turkey.
Full EKIVF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.